RWP
CTXR icon

RWA Wealth Partners’s Citius Pharmaceuticals CTXR Stock Holding History

RWA Wealth Partners’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-400
Closed -$35K – 239
2021
Q2 		$35K Hold
400
– – ﹤0.01% 242
2021
Q1 		$18K Buy
+400
New +$15.9K ﹤0.01% 237

Other funds holding CTXR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

RWA Wealth Partners's CTXR Position: Q3 2021 in Review

RWA Wealth Partners sold out of Citius Pharmaceuticals (CTXR) in Q3 2021, closing a stake of 400 shares — an estimated $35K sold.

RWA Wealth Partners first reported a position in CTXR in Q1 2021 and held it in 2 quarters. The position peaked at $35K in Q2 2021. 71 funds tracked by Wall St. Rank hold CTXR as of Q3 2021.

  • RWA Wealth Partners reported no remaining Citius Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • RWA Wealth Partners sold 400 Citius Pharmaceuticals shares in Q3 2021, an estimated $35K.
  • RWA Wealth Partners first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • RWA Wealth Partners's Citius Pharmaceuticals position peaked at $35K in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q3 2021.

Based on RWA Wealth Partners's 13F filing for Q3 2021, filed 5 Nov 2021.